Nanobiotix S.A. has an institutional holder group led by Invus Public Equities, L.P. reporting beneficial ownership of 4,483,275 ordinary shares and 345,099 pre-funded warrants, each exercisable for one share at Euro 0.03 per share and expiring May 26, 2036.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Nanobiotix S.A. has an institutional holder group led by Invus Public Equities, L.P. reporting beneficial ownership of 4,483,275 ordinary shares and 345,099 pre-funded warrants, each exercisable for one share at Euro 0.03 per share and expiring May 26, 2036. Based on 50,807,903 shares outstanding as of May 31, 2026, plus the warrant shares, the Invus-related reporting persons each may be deemed to beneficially own 4,828,374 shares, or 9.4% of the company. The group reports sole voting and dispositive power over these securities and certifies that the holdings are not for the purpose of changing or influencing control. Nanobiotix ADSs, each representing one ordinary share, trade under the symbol NBTX and use CUSIP 63009J107.
Key Figures
Ordinary shares held:4,483,275 sharesPre-Funded Warrants:345,099 warrantsExercise price:Euro 0.03 per Share+5 more
8 metrics
Ordinary shares held4,483,275 sharesOrdinary shares of Nanobiotix S.A. directly held by Invus Public Equities as of June 30, 2026
Pre-Funded Warrants345,099 warrantsIssuer Pre-Funded Warrants held by Invus Public Equities, exercisable one-for-one into shares
Exercise priceEuro 0.03 per ShareExercise price of each Pre-Funded Warrant
Warrant expirationMay 26, 2036Expiration date of the Pre-Funded Warrants
Beneficially owned shares4,828,374 sharesTotal shares deemed beneficially owned by each reporting person, including warrant shares
Ownership percentage9.4%Percent of Nanobiotix ordinary shares beneficially owned as of June 30, 2026
Shares outstanding baseline50,807,903 sharesNanobiotix shares outstanding as of May 31, 2026, used in ownership calculation
CUSIP for ADSs63009J107CUSIP assigned to Nanobiotix American Depositary Shares trading under symbol NBTX
Key Terms
Pre-Funded Warrants, beneficially own, American Depositary Shares, Sole Voting Power, +1 more
5 terms
Pre-Funded Warrantsfinancial
"345,099 Issuer Pre-Funded Warrants exercisable for Shares on a one-for-one basis"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
beneficially ownfinancial
"may be deemed to beneficially own the Shares directly held by Invus Public Equities"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
American Depositary Sharesfinancial
"The CUSIP Number 63009J107 has been assigned to the American Depositary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
Sole Voting Powerfinancial
"5 | Sole Voting Power 4,828,374.00 6 | Shared Voting Power 0.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
Sole Dispositive Powerfinancial
"7 | Sole Dispositive Power 4,828,374.00 8 | Shared Dispositive Power 0.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much of Nanobiotix S.A. (NBTX) do the Invus entities beneficially own?
The Invus-related reporting persons may be deemed to beneficially own 4,828,374 shares of Nanobiotix S.A., representing 9.4% of the ordinary shares, including shares underlying pre-funded warrants exercisable on a one-for-one basis.
What Nanobiotix S.A. (NBTX) securities does Invus Public Equities directly hold?
Invus Public Equities directly holds 4,483,275 ordinary shares and 345,099 pre-funded warrants of Nanobiotix S.A. Each warrant is exercisable for one share at an exercise price of Euro 0.03 per share and expires on May 26, 2036.
How was the 9.4% ownership of Nanobiotix S.A. (NBTX) calculated?
The 9.4% figure is based on 50,807,903 shares outstanding as of May 31, 2026, plus 345,099 shares issuable upon exercise of certain pre-funded warrants held by Invus Public Equities, as referenced in the company’s Form 6-K.
Do the Invus reporting persons seek to influence control of Nanobiotix S.A. (NBTX)?
The reporting persons certify that the Nanobiotix securities were not acquired and are not held for the purpose or effect of changing or influencing control, other than activities solely in connection with a nomination under Item 11.
What is the relationship between Nanobiotix S.A. ordinary shares and its ADSs (NBTX)?
Nanobiotix has American Depositary Shares (ADSs) quoted under the symbol NBTX, with CUSIP 63009J107. Each ADS represents one ordinary share of Nanobiotix S.A., which itself has no separate CUSIP number.
Who are the key entities in the Invus reporting group for Nanobiotix S.A. (NBTX)?
The reporting group includes Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., and Raymond Debbane, with control relationships causing each to be deemed a beneficial owner of the same shares.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Nanobiotix S.A.
(Name of Issuer)
Ordinary shares, nominal value Euro 0.03 per share
(Title of Class of Securities)
63009J107
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
63009J107
1
Names of Reporting Persons
Invus Public Equities, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
BERMUDA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
4,828,374.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
4,828,374.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,828,374.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.4 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: There is no CUSIP number assigned to the Ordinary shares, nominal value Euro 0.03 per share (the "Shares") of Nanobiotix S.A. (the "Issuer"). The CUSIP Number 63009J107 has been assigned to the American Depositary Shares ("ADSs") of the Issuer, which are quoted on the Nasdaq Global Market under the symbol "NBTX"; each ADS represents 1 Share.
SCHEDULE 13G
CUSIP Number(s):
63009J107
1
Names of Reporting Persons
Invus Public Equities Advisors, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
4,828,374.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
4,828,374.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,828,374.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.4 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: There is no CUSIP number assigned to the Ordinary shares, nominal value Euro 0.03 per share (the "Shares") of Nanobiotix S.A. (the "Issuer"). The CUSIP Number 63009J107 has been assigned to the American Depositary Shares ("ADSs") of the Issuer, which are quoted on the Nasdaq Global Market under the symbol "NBTX"; each ADS represents 1 Share.
SCHEDULE 13G
CUSIP Number(s):
63009J107
1
Names of Reporting Persons
Invus Global Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
4,828,374.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
4,828,374.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,828,374.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.4 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: There is no CUSIP number assigned to the Ordinary shares, nominal value Euro 0.03 per share (the "Shares") of Nanobiotix S.A. (the "Issuer"). The CUSIP Number 63009J107 has been assigned to the American Depositary Shares ("ADSs") of the Issuer, which are quoted on the Nasdaq Global Market under the symbol "NBTX"; each ADS represents 1 Share.
SCHEDULE 13G
CUSIP Number(s):
63009J107
1
Names of Reporting Persons
Siren, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
4,828,374.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
4,828,374.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,828,374.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.4 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: There is no CUSIP number assigned to the Ordinary shares, nominal value Euro 0.03 per share (the "Shares") of Nanobiotix S.A. (the "Issuer"). The CUSIP Number 63009J107 has been assigned to the American Depositary Shares ("ADSs") of the Issuer, which are quoted on the Nasdaq Global Market under the symbol "NBTX"; each ADS represents 1 Share.
SCHEDULE 13G
CUSIP Number(s):
63009J107
1
Names of Reporting Persons
Raymond Debbane
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
PANAMA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
4,828,374.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
4,828,374.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,828,374.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.4 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: There is no CUSIP number assigned to the Ordinary shares, nominal value Euro 0.03 per share (the "Shares") of Nanobiotix S.A. (the "Issuer"). The CUSIP Number 63009J107 has been assigned to the American Depositary Shares ("ADSs") of the Issuer, which are quoted on the Nasdaq Global Market under the symbol "NBTX"; each ADS represents 1 Share.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Nanobiotix S.A.
(b)
Address of issuer's principal executive offices:
60 rue de Wattignies, 75012 Paris, France
Item 2.
(a)
Name of person filing:
See Item 2(c) below.
(b)
Address or principal business office or, if none, residence:
See Item 2(c) below.
(c)
Citizenship:
(i) Invus Public Equities, L.P. ("Invus Public Equities")
750 Lexington Avenue, 30th Floor, New York, NY 10022
Citizenship: Bermuda limited partnership
(ii) Invus Public Equities Advisors, LLC ("Invus PE Advisors")
750 Lexington Avenue, 30th Floor, New York, NY 10022
Citizenship: Delaware limited liability company
(iii) Invus Global Management, LLC ("Global Management")
750 Lexington Avenue, 30th Floor, New York, NY 10022
Citizenship: Delaware limited liability company
(iv) Siren, L.L.C. ("Siren")
c/o The Invus Group, LLC, 750 Lexington Avenue, 30th Floor, New York, NY 10022
Citizenship: Delaware limited liability company
(v) Raymond Debbane
750 Lexington Avenue, 30th Floor, New York, NY 10022
Citizenship: Panama
(d)
Title of class of securities:
Ordinary shares, nominal value Euro 0.03 per share
(e)
CUSIP No.:
63009J107
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As of June 30, 2026, Invus Public Equities directly held 4,483,275 Ordinary shares, Euro 0.03 nominal value per share (the "Shares") of Nanobiotix S.A. (the "Issuer") and 345,099 Issuer Pre-Funded Warrants exercisable for Shares on a one-for-one basis (the "Warrants"). Each of the Pre-Funded Warrants has an exercise price of Euro 0.03 per Share and an expiration date of May 26, 2036. Invus PE Advisors, as the general partner of Invus Public Equities, controls Invus Public Equities and, accordingly, may be deemed to beneficially own the Shares directly held by Invus Public Equities. Global Management, as the managing member of Invus PE Advisors, controls Invus PE Advisors and, accordingly, may be deemed to beneficially own the Shares that Invus PE Advisors may be deemed to beneficially own. Siren, as the managing member of Global Management, controls Global Management and, accordingly, may be deemed to beneficially own the Shares that Global Management may be deemed to beneficially own. Mr. Raymond Debbane, as the managing member of Siren, controls Siren and, accordingly, may be deemed to beneficially own the Shares that Siren may be deemed to beneficially own.
There is no CUSIP number assigned to the Shares. The CUSIP Number 63009J107 has been assigned to the American Depositary Shares ("ADS") of the Issuer, which are quoted on the Nasdaq Global Market under the symbol "NBTX"; each ADS represents 1 Share.
(b)
Percent of class:
As of June 30, 2026, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person's cover page. Calculations of the percentage of Shares beneficially owned are based on (i) 50,807,903 Shares outstanding as of May 31, 2026, as reported in the Issuer's Form 6-K filed with the Securities and Exchange Commission on June 5, 2026, plus (ii) 345,099 Shares issuable upon exercise of certain of the Warrants.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See each cover page hereof.
(ii) Shared power to vote or to direct the vote:
See each cover page hereof.
(iii) Sole power to dispose or to direct the disposition of:
See each cover page hereof.
(iv) Shared power to dispose or to direct the disposition of:
See each cover page hereof.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Each of the Reporting Persons hereby makes the following certification:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Invus Public Equities, L.P.
Signature:
/s/ Raymond Debbane
Name/Title:
Raymond Debbane, President of Invus Public Equities Advisors, LLC, its general partner
